Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals

American Journal of Cardiology

Volumn 77, Issue 10, 1996, Pages 832-838

  Philbin, Edward F ^a   Andreou, Costa ^b   Rocco Jr , Thomas A ^b   Lynch, Laura J ^b   Baker, Sharon L ^b  

^a BASSETT HEALTHCARE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; COMMUNITY HOSPITAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG USE; FEMALE; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0029943840     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89177-1     Document Type: Article

References (25)

1. Captopril Multicenter Research Group. A placebo-controlled trial of refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-763.
2. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847-853.
3. Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988;62:67A-72A.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1994;23:393-400.
7. Cohn JN, Johnson G, Zieshe S, Cobb F, Francis G, Tritsani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
8. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
9. Weber KT, Bauer JH, Villareal D, Sun Y. Role of angiotensin-converting enzyme inhibition in the management of heart failure: present and future roles. Congestive Heart Failure 1995;1:16-23.
10. Paul SD, Kuntz KM, Eagle KA, Weinstein NC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-1149.
11. Konstam MA, Dracup K, Bottoroff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF. Quick Reference Guide For Clinicians No. 11: Heart Failure: Management of Patients With Left Ventricular Systolic Dysfunction. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services, 1994. AHCPR (publication no. 94-0613).
12. Massie BM, Amidon T. Angiotensin-converting enzyme inhibitor therapy for congestive heart failure: rationale, results, and current recommendations. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. New York: Springer-Verlag, 1994:380-399.
13. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-S112.
14. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993;22(suppl A):198A-200A.
15. U. S. Department of Health and Human Services, Public Health Service, Health Care Financing Administration. Coding Clinic For ICD-9-CM. 4th ed. vol. 1-3. Chicago, IL: American Hospital Association, 1994.
16. 3M Health Information Services, U.S. Health Care Financing Administration. Diagnosis Related Groups Definitions Manual. Wallingford, CT: 3M Health Information Services, 1993.
17. 3M Health Information Services, New York State Department of Health Division of Health Care Financing. All Patient Diagnosis Related Groups Definitions Manual. Wallingford, CT: 3M Health Information Services, 1993.
18. Brophy JM, DesLauriers G, Boucher B, Rouleau JL. The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1993;9:219-224.
19. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-1162.
20. Mohan P, Hii JT, Wuttke RD, Esterman AJ, Hollington P, Horowitz JD. Acute heart failure: determinants of outcome. Int J Cardiol 1991;32:365-376.
21. Gradman AH, Deedwania PC. Predictors of mortality in patients with heart failure. Cardiol Clin 1994;12:25-35.
22. SAS Institute Inc. SAS/STAT User's Guide, version 6. 4th ed. vols 1-2. Cary, NC: SAS Institute Inc., 1989.
23. Suki WN. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989;149:669-673.
24. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992;117:502-510.
25. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tritsani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.